Stem Cell Transplant for Common Variable Immunodeficiency
(CVID/PIRD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a research protocol that will examine Hematopoietic Stem Cell Transplantation (HSCT) using a reduced conditioning regimen (RIC) with total body Irradiation (TBI) in those diagnosed with Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD).
Who Is on the Research Team?
Paul Szabolcs, MD
Principal Investigator
UPMC Children's Hospital of Pittsburgh
Are You a Good Fit for This Trial?
Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Hematopoietic stem cell transplant (HSCT)
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
The participant will receive an allogenic, fully (8 of 8 match) or partially HLA-matched (6-7/8 HLA-matched), stem cell transplant utilizing a conditioning regimen of alemtuzumab/Campath, anti-thymocyte globulin/rabbit ATG, Fludarabine and Melphalan and total body irradiation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Paul Szabolcs
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.